Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Schizophrenia

Free Subscription Articles published in Neuropsychopharmacology Retrieve available abstracts of 33 articles: HTML format

Single Articles

March 2023
1. O'DONNELL P, Dong C, Murthy V, Asgharnejad M, et al
   The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
   Neuropsychopharmacology. 2023 Mar 16. doi: 10.1038/s41386-023-01560.
   PubMed     Abstract available
   
   
   February 2023
2. CHEN X, Song X, Ongur D, Du F, et al
   Association of default-mode network neurotransmitters and inter-network functional connectivity in first episode psychosis.
   Neuropsychopharmacology. 2023 Feb 14. doi: 10.1038/s41386-023-01546.
   PubMed     Abstract available
   
   
   December 2022
3. YANG C, Zhang W, Liu J, Yao L, et al
   Disrupted subcortical functional connectome gradient in drug-naive first-episode schizophrenia and the normalization effects after antipsychotic treatment.
   Neuropsychopharmacology. 2022 Dec 10. doi: 10.1038/s41386-022-01512.
   PubMed     Abstract available
   
   
   
4. EGERTON A, Griffiths K, Casetta C, Deakin B, et al
   Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration.
   Neuropsychopharmacology. 2022 Dec 1. doi: 10.1038/s41386-022-01508.
   PubMed     Abstract available
   
   
   November 2022
5. MOYA NA, Yun S, Fleps SW, Martin MM, et al
   The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
   Neuropsychopharmacology. 2022 Nov 15. pii: 10.1038/s41386-022-01492.
   PubMed     Abstract available
   
   
   
6. FENG N, Palaniyappan L, Robbins TW, Cao L, et al
   Working memory processing deficit associated with a nonlinear response pattern of the anterior cingulate cortex in first-episode and drug-naive schizophrenia.
   Neuropsychopharmacology. 2022 Nov 14. pii: 10.1038/s41386-022-01499.
   PubMed     Abstract available
   
   
   October 2022
7. LENCZ T, Moyett A, Argyelan M, Barber AD, et al
   Frontal lobe fALFF measured from resting-state fMRI as a prognostic biomarker in first-episode psychosis.
   Neuropsychopharmacology. 2022 Oct 5. pii: 10.1038/s41386-022-01470.
   PubMed     Abstract available
   
   
   September 2022
8. VINOGRADOV S, Chafee MV, Lee E, Morishita H, et al
   Psychosis spectrum illnesses as disorders of prefrontal critical period plasticity.
   Neuropsychopharmacology. 2022 Sep 30. pii: 10.1038/s41386-022-01451.
   PubMed     Abstract available
   
   
   
9. HOWES OD, Cummings C, Chapman GE, Shatalina E, et al
   Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes.
   Neuropsychopharmacology. 2022 Sep 2. pii: 10.1038/s41386-022-01426.
   PubMed     Abstract available
   
   
   August 2022
10. SCHWARZER JM, Meyhoefer I, Antonucci LA, Kambeitz-Ilankovic L, et al
    The impact of visual dysfunctions in recent-onset psychosis and clinical high-risk state for psychosis.
    Neuropsychopharmacology. 2022 Aug 18. pii: 10.1038/s41386-022-01385.
    PubMed     Abstract available
    
    
    March 2022
11. ALNAFISAH RS, Reigle J, Eladawi MA, O'Donovan SM, et al
    Assessing the effects of antipsychotic medications on schizophrenia functional analysis: a postmortem proteome study.
    Neuropsychopharmacology. 2022 Mar 30. pii: 10.1038/s41386-022-01310.
    PubMed     Abstract available
    
    
    
12. ZHAO Q, Cao H, Zhang W, Li S, et al
    A subtype of institutionalized patients with schizophrenia characterized by pronounced subcortical and cognitive deficits.
    Neuropsychopharmacology. 2022 Mar 8. pii: 10.1038/s41386-022-01300.
    PubMed     Abstract available
    
    
    
13. TSITSIPA E, Rogers J, Casalotti S, Belessiotis-Richards C, et al
    Selective 5HT3 antagonists and sensory processing: a systematic review.
    Neuropsychopharmacology. 2022;47:880-890.
    PubMed     Abstract available
    
    
    
14. DAO M, Stoveken HM, Cao Y, Martemyanov KA, et al
    The role of orphan receptor GPR139 in neuropsychiatric behavior.
    Neuropsychopharmacology. 2022;47:902-913.
    PubMed     Abstract available
    
    
    February 2022
15. SEHATPOUR P, Javitt DC, De Baun HM, Carlson M, et al
    Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
    Neuropsychopharmacology. 2022;47:711-718.
    PubMed     Abstract available
    
    
    January 2022
16. KIMOTO S, Hashimoto T, Berry KJ, Tsubomoto M, et al
    Expression of actin- and oxidative phosphorylation-related transcripts across the cortical visuospatial working memory network in unaffected comparison and schizophrenia subjects.
    Neuropsychopharmacology. 2022 Jan 15. pii: 10.1038/s41386-022-01274.
    PubMed     Abstract available
    
    
    
17. CARREIRA FIGUEIREDO I, Borgan F, Pasternak O, Turkheimer FE, et al
    White-matter free-water diffusion MRI in schizophrenia: a systematic review and meta-analysis.
    Neuropsychopharmacology. 2022 Jan 15. pii: 10.1038/s41386-022-01272.
    PubMed     Abstract available
    
    
    November 2021
18. KIEMES A, Gomes FV, Cash D, Uliana DL, et al
    GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia.
    Neuropsychopharmacology. 2021 Nov 6. pii: 10.1038/s41386-021-01213.
    PubMed     Abstract available
    
    
    October 2021
19. KIM M, Lee TH, Park H, Moon SY, et al
    Thalamocortical dysrhythmia in patients with schizophrenia spectrum disorder and individuals at clinical high risk for psychosis.
    Neuropsychopharmacology. 2021 Oct 4. pii: 10.1038/s41386-021-01180.
    PubMed     Abstract available
    
    
    
20. PELIN H, Ising M, Stein F, Meinert S, et al
    Identification of transdiagnostic psychiatric disorder subtypes using unsupervised learning.
    Neuropsychopharmacology. 2021;46:1895-1905.
    PubMed     Abstract available
    
    
    September 2021
21. TUOMINEN L, Romaniuk L, Milad MR, Goff DC, et al
    Impairment in acquisition of conditioned fear in schizophrenia.
    Neuropsychopharmacology. 2021 Sep 29. pii: 10.1038/s41386-021-01193.
    PubMed     Abstract available
    
    
    
22. MILLARD SJ, Bearden CE, Karlsgodt KH, Sharpe MJ, et al
    The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity.
    Neuropsychopharmacology. 2021 Sep 29. pii: 10.1038/s41386-021-01188.
    PubMed     Abstract available
    
    
    
23. EUM S, Hill SK, Alliey-Rodriguez N, Stevenson JM, et al
    Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.
    Neuropsychopharmacology. 2021;46:1802-1810.
    PubMed     Abstract available
    
    
    
24. LAM M, Chen CY, Ge T, Xia Y, et al
    Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics.
    Neuropsychopharmacology. 2021;46:1788-1801.
    PubMed     Abstract available
    
    
    August 2021
25. ABDALLAH CG, Mason GF
    Novel approaches to estimate prefrontal synaptic strength in vivo in humans: of relevance to depression, schizophrenia, and ketamine.
    Neuropsychopharmacology. 2021 Aug 2. pii: 10.1038/s41386-021-01122.
    PubMed    
    
    
    
26. BRALTEN J, Mota NR, Klemann CJHM, De Witte W, et al
    Genetic underpinnings of sociability in the general population.
    Neuropsychopharmacology. 2021;46:1627-1634.
    PubMed     Abstract available
    
    
    July 2021
27. SMUCNY J, Dienel SJ, Lewis DA, Carter CS, et al
    Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia.
    Neuropsychopharmacology. 2021 Jul 20. pii: 10.1038/s41386-021-01089.
    PubMed     Abstract available
    
    
    
28. FERRARELLI F, Phillips ML
    PFC neuromodulation with theta burst stimulation to impact behavior and neural network activity in schizophrenia and bipolar disorder.
    Neuropsychopharmacology. 2021 Jul 7. pii: 10.1038/s41386-021-01086.
    PubMed    
    
    
    
29. GOLDWASER EL, Chiappelli J, Kvarta MD, Du X, et al
    White matter in prolonged glucocorticoid response to psychological stress in schizophrenia.
    Neuropsychopharmacology. 2021 Jul 1. pii: 10.1038/s41386-021-01077.
    PubMed     Abstract available
    
    
    June 2021
30. AVRAM M, Grothe MJ, Meinhold L, Leucht C, et al
    Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia.
    Neuropsychopharmacology. 2021 Jun 29. pii: 10.1038/s41386-021-01070.
    PubMed     Abstract available
    
    
    
31. TRONCHIN G, Akudjedu TN, Ahmed M, Holleran L, et al
    Correction to: Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.
    Neuropsychopharmacology. 2021 Jun 24. pii: 10.1038/s41386-021-01062.
    PubMed    
    
    
    May 2021
32. MODINOS G, Richter A, Egerton A, Bonoldi I, et al
    Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes.
    Neuropsychopharmacology. 2021 May 3. pii: 10.1038/s41386-021-01019.
    PubMed     Abstract available
    
    
    April 2021
33. SEITZ-HOLLAND J, Seethaler M, Makris N, Rushmore J, et al
    The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study.
    Neuropsychopharmacology. 2021 Apr 8. pii: 10.1038/s41386-021-00997.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: